Main Article Content

Abstract

Ivermectin is an antiparasitic drug that is a synthetic version of avermectin. It is used in veterinary medicine and to treat onchocerciasis in humans. It binds to glutamate gated chloride channels and has now been targeted to treat the microfilaria stage of various parasites. The US Food and Drug Administration have approved ivermectin lotion for the treatment of pediculosis capitis. Oral ivermectin is used to treat phthiriasis palpebraum and is effective against a wide variety of nematodes and insects, as well as acarine of animals and humans.


 

Keywords

Ivermectin onchocerciasis microfilaria capitis scabies filariasis

Article Details

How to Cite
A.Hussain, SP.Senthil, M.Sakthivel, & R.Senthamarai. (2021). Review on ivermectin. International Journal of Research in Pharmacology & Pharmacotherapeutics, 10(3), 219-224. Retrieved from https://ijrpp.com/ijrpp/article/view/395

References

  1. 1. del Giudice P, Marty P. Ivermectin: a new therapeutic weapon in dermatology? Arch Dermatol. 1999 Jun 1; 135(6):705-6. doi: 10.1001/archderm.135.6.705, PMID 10376699.
  2. 2. Turner MJ, Schaeffer JM. Mode of action of ivermectin. InIvermectin and Abamectin 1989 (pp. 73-88). New York: Springer.
  3. 3. Dent JA, Davis MW, Avery L. Avr 15 encodes a chloride channel subunit that mediates inhibitory glutamatergic neurotransmission and ivermectin sensitivity in Caenorhabditis elegans. EMBO J. 1997 Oct 1; 16(19):5867-79. doi: 10.1093/emboj/16.19.5867, PMID 9312045.
  4. 4. Burkhart CN, Burkhart CG. Ivermectin: a few caveats are warranted before initiating therapy for scabies. Arch Dermatol. 1999 Dec 1; 135(12):1549-50. doi: 10.1001/archderm.135.12.1549, PMID 10606071.
  5. 5. Campbell WC. Ivermectin, an antiparasitic agent. Med Res Rev. 1993 Jan; 13(1):61-79. doi: 10.1002/med.2610130103, PMID 8416263.
  6. 6. Edwards G, Dingsdale A, Helsby N, Orme ML, Breckenridge AM. The relative systemic availability of ivermectin after administration as capsule, tablet, and oral solution. Eur J Clin Pharmacol. 1988 Nov; 35(6):681-4. doi: 10.1007/BF00637608, PMID 3234475.
  7. 7. Fink DW, Porras AG. Pharmacokinetics of ivermectin in animals and humans. InIvermectin and Abamectin 1989 (pp. 113-30). New York: Springer.
  8. 8. González Canga A, Sahagún Prieto AM, Diez Liébana MJ, Fernández Martínez N, Sierra Vega M, García Vieitez JJ. The pharmacokinetics and interactions of ivermectin in humans—a mini-review. AAPS J. 2008 Mar;10(1):42-6. doi: 10.1208/s12248-007-9000-9, PMID 18446504.
  9. 9. Baraka OZ, Mahmoud BM, Marschke CK, Geary TG, Homeida MM, Williams JF. Ivermectin distribution in the plasma and tissues of patients infected with Onchocerca volvulus. Eur J Clin Pharmacol. 1996 Jul;50(5):407-10. doi: 10.1007/s002280050131, PMID 8839664.
  10. 10. Haas N, Lindemann U, Frank K, Sterry W, Lademann J, Katzung W. Rapid and preferential sebum secretion of ivermectin: a new factor that may determine drug responsiveness in patients with scabies. Arch Dermatol. 2002 Dec 1;138(12):1618-9. doi: 10.1001/archderm.138.12.1618, PMID 12472363.
  11. 11. Chhaiya SB, Mehta DS, Kataria BC. Ivermectin: pharmacology and therapeutic applications. Int J Basic Clin Pharmacol. 2012 Nov;1(3):132-9. doi: 10.5455/2319-2003.ijbcp002712.
  12. 12. Paasch U, Haustein UF. Management of endemic outbreaks of scabies with allethrin, permethrin, and ivermectin. Int J Dermatol. 2000 Jun;39(6):463-70. doi: 10.1046/j.1365-4362.2000.00990.x, PMID 10944095.
  13. 13. Hoerauf A, Mand S, Adjei O, Fleischer B, Büttner DW. Depletion of Wolbachia endobacteria in Onchocerca volvulus by doxycycline and microfilaridermia after ivermectin treatment. Lancet. 2001 May 5;357(9266):1415-6. doi: 10.1016/S0140-6736(00)04581-5, PMID 11356444.
  14. 14. Awadzi K, Edwards G, Opoku NO, Ardrey AE, Favager S, Addy ET, Attah SK, Yamuah LK, Quartey BT. The safety, tolerability and pharmacokinetics of levamisole alone, levamisole plus ivermectin, and levamisole plus albendazole, and their efficacy against Onchocerca volvulus. Ann Trop Med Parasitol. 2004 Sep 1;98(6):595-614. doi: 10.1179/000349804225021370, PMID 15324466.
  15. 15. Ismail MM, Jayakody RL. Efficacy of albendazole and its combinations with ivermectin or diethylcarbamazine (DEC) in the treatment of Trichuris trichiura infections in Sri Lanka. Ann Trop Med Parasitol. 1999 Jul 1;93(5):501-4. doi: 10.1080/00034989958230, PMID 10690245.
  16. 16. González Canga A, Sahagún Prieto AM, Diez Liébana MJ, Fernández Martínez N, Sierra Vega M, García Vieitez JJ. The pharmacokinetics and interactions of ivermectin in humans—a mini-review. AAPS J. 2008 Mar;10(1):42-6. doi: 10.1208/s12248-007-9000-9, PMID 18446504.
  17. 17. Shu EN, Onwujekwe EO, Okonkwo PO. Do alcoholic beverages enhance availability of ivermectin? Eur J Clin Pharmacol. 2000 Aug 1;56(5):437-8. doi: 10.1007/s002280000120, PMID 11009055.
  18. 18. Vanapalli SR, Chen Y, Ellingrod VL, Kitzman D, Lee Y, Hohl RJ, Fleckenstein L. Orange juice decreases the oral bioavailability of ivermectin in healthy volunteers. Clin Pharmacol Ther. 2003 Feb;73(2):P94--. doi: 10.1016/S0009-9236(03)90702-8.
  19. 19. Gowtham S, Karthikeyan K. Wonder drug for worms: a review of three decades of ivermectin use in dermatology. Indian J Dermatol Venereol Leprol. 2019 Nov 1;85(6):674-8. doi: 10.4103/ijdvl.IJDVL_840_18, PMID 31552839.
  20. 20. Wilkins AL, Steer AC, Cranswick N, Gwee A. Question 1: is it safe to use ivermectin in children less than five years of age and weighing less than 15 kg? Arch Dis Child. 2018 May 1;103(5):514-9. doi: 10.1136/archdischild-2017-314505, PMID 29463522.
  21. 21. Dang K, Tribble AC. Strategies in infectious disease prevention and management among US-bound refugee children. Curr Probl Pediatr Adolesc Health Care. 2014 Aug 1;44(7):196-207. doi: 10.1016/j.cppeds.2014.03.004, PMID 25042432.
  22. 22. Chhaiya SB, Patel VJ, Dave JN, Mehta DS, Shah HA. Comparative efficacy and safety of topical permethrin, topical ivermectin, and oral ivermectin in patients of uncomplicated scabies. Indian J Dermatol Venereol Leprol. 2012 Sep 1;78(5):605-10. doi: 10.4103/0378-6323.100571, PMID 22960817.
  23. 23. Sangaré AK, Doumbo OK, Raoult D. Management and treatment of human lice. BioMed Res Int. 2016 Jul 27;2016:8962685. doi: 10.1155/2016/8962685, PMID 27529073.
  24. 24. Chosidow O, Giraudeau B, Cottrell J, Izri A, Hofmann R, Mann SG, Burgess I. Oral ivermectin versus Malathion lotion for difficult-to-treat head lice. N Engl J Med. 2010 Mar 11;362(10):896-905. doi: 10.1056/NEJMoa0905471, PMID 20220184.
  25. 25. Salavastru CM, Chosidow O, Janier M, Tiplica GS. European guideline for the management of pediculosis pubis. J Eur Acad Dermatol Venereol. 2017 Sep;31(9):1425-8. doi: 10.1111/jdv.14420, PMID 28714128.
  26. 26. Rather PA, Hassan I. Human demodex mite: the versatile mite of dermatological importance. Indian J Dermatol. 2014 Jan;59(1):60-6. doi: 10.4103/0019-5154.123498, PMID 24470662.
  27. 27. Dourmishev AL, Dourmishev LA, Schwartz RA. Ivermectin: pharmacology and application in dermatology. Int J Dermatol. 2005 Dec;44(12):981-8. doi: 10.1111/j.1365-4632.2004.02253.x, PMID 16409259.
  28. 28. Gowtham S, Karthikeyan K. Wonder drug for worms: a review of three decades of ivermectin use in dermatology. Indian J Dermatol Venereol Leprol. 2019 Nov 1;85(6):674-8. doi: 10.4103/ijdvl.IJDVL_840_18, PMID 31552839.
  29. 29. Chhaiya SB, Mehta DS, Kataria BC. Ivermectin: pharmacology and therapeutic applications. Int J Basic Clin Pharmacol. 2012 Nov;1(3):132-9. doi: 10.5455/2319-2003.ijbcp002712.
  30. 30. Karthikeyan K, Thappa DM. Cutaneous larva migrans. Indian J Dermatol Venereol Leprol. 2002 Sep 1;68(5):252-8. PMID 17656960.
  31. 31. Albrecht H, Franco-Paredes C. Cutaneous larva migrans. Infect Dis. 1998;1998.
  32. 32. Shorman M, Al-Tawfiq JA. Strongyloides stercoralis hyperinfection presenting as acute respiratory failure and Gram-negative sepsis in a patient with astrocytoma. Int J Infect Dis. 2009 Sep 1;13(5):e288-91. doi: 10.1016/j.ijid.2008.11.019, PMID 19231269.
  33. 33. Boussinesq M. Loiasis: new epidemiologic insights and proposed treatment strategy. J Travel Med. 2012 May 1;19(3):140-3. doi: 10.1111/j.1708-8305.2012.00605.x, PMID 22530819.